 |
|
|
|
 |
|
|
| Article 1 to 10 out of 108 concerning Galapagos NV
|
-
Galapagos successfully completes Phase I clinical trials for rheumatoid arthritis candidate drug GLPG0259
(25 Feb 2010)
Phase II efficacy study in rheumatoid arthritis patients planned to start later this year
Galapagos NV announced that it has completed Phase I clinical trials for GLPG0259, a novel mechanism-of-action candidate drug being developed for rheumatoid arthritis (RA). These results support the design of a Phase II study planned to start later ...
-
Galapagos and MorphoSys expand antibody alliance
(18 Feb 2010)
Galapagos NV and MorphoSys AG announced that they have expanded their antibody alliance in bone & joint diseases. Based on the progress made so far, the partners have agreed to add another antibody target to the alliance, thereby increasing the ...
-
Galapagos acquires Argenta Discovery's service operations
(04 Feb 2010)
Galapagos NV announced the acquisition of Argenta Discovery 2009 Ltd., a privately held contract research drug discovery company with 140 employees. The combination with Galapagos' service division BioFocus creates a drug discovery service ...
-
Galapagos candidate metastasis drug shows good safety and biomarker response
(20 Jan 2010)
Successful conclusion of first clinical trial for GLPG0187
Galapagos NV announced results from the first-in-human trial with candidate drug GLPG0187. GLPG0187 offers a new approach to treat metastases, a severe complication of many cancers. The candidate drug showed good safety and a promising biomarker ...
-
Galapagos achieves milestones in strategic alliances with Merck & Co., Inc.
(19 Jan 2010)
Galapagos NV announced that it has reached milestones in both of its global strategic alliances with an affiliate of Merck & Co., Inc. The achievement of these milestones has entitled Galapagos to receive an aggregate payment of EUR 3.6 million ...
-
Galapagos and Roche initiate strategic alliance in COPD
(13 Jan 2010)
Research access payment of EUR 6 million for Galapagos
Galapagos NV announced that it has entered into a global multi-year strategic alliance with Roche to develop potential new therapies in COPD (chronic obstructive pulmonary disease).In the alliance, Galapagos will apply its target discovery platform ...
-
Galapagos and GlaxoSmithKline broaden arthritis alliance
(17 Dec 2009)
Expansion of programs based on promising drug target GT622 €6.5 M payment this year and additional milestones
Galapagos NV announced that it has expanded its arthritis alliance with GlaxoSmithKline to include additional drug discovery programs based on novel drug target GT622. Under the terms of this extension, Galapagos will receive a payment from GSK of ...
-
Galapagos receives €4 M milestone for first clinical trial in GlaxoSmithKline alliance
(08 Dec 2009)
Galapagos NV announced that it has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK). For entering the clinic with candidate drug GLPG0555, Galapagos receives a ...
-
Galapagos achieves multiple milestones in rheumatoid arthritis alliance
(04 Dec 2009)
Galapagos NV announced achievement of multiple milestones under its alliance agreement in rheumatoid arthritis. The milestones trigger a cash payment of €10.2 million to Galapagos.In October 2007, Galapagos announced an alliance agreement with ...
-
Galapagos receives EUREKA innovation label and OSEO funding
(27 Nov 2009)
Galapagos NV announced that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO. Accordingly, the Paris-based Galapagos R&D center will receive interest free loans ...
Additional information
Galapagos NV
Mechelen, Belgium
Company
|
|
|
|
|
|
Top
